LITTLETON, Mass.--(BUSINESS WIRE)--Mevion Medical Systems, the leader in compact proton therapy, is announcing a strategic agreement with medPhoton GmbH to integrate ImagingRing, an innovative cone beam computed tomography (CBCT) system for volumetric image guidance, with the MEVION S250i with HYPERSCAN, Mevion’s pencil-beam scanning proton therapy system. The new CBCT offering will debut this week at the 36th annual meeting of the European Society for Radiotherapy & Oncology (ESTRO), at booth #2500.
This agreement represents the latest advance in Mevion’s transformative approach to proton therapy. By adding fully integrated cone beam imaging to Mevion’s suite of in-room image guidance capabilities, Mevion and medPhoton provide simplicity of workflow and more precise and efficient treatment delivery.
“The agreement with Mevion provides us the opportunity to integrate the industry's most compact proton therapy system, the MEVION S250 Series, with our slim, multi-purpose in-room CBCT system, providing large field-of-view, cutting edge acquisition speed, spatial resolution, and outstanding low contrast visibility at very low doses,” said Heinz Deutschmann, chief executive officer and founder of medPhoton. “We believe the products will complement each other and enable clinicians to truly optimize the proton treatments they can provide their patients.”
CBCT imaging is an important capability in the treatment room to precisely position patients for pencil beam proton therapy. In-room CBCT, when integrated to Mevion’s Verity image-guided patient positioning system will enable users to treat patients with the latest image guided radiation therapy (IGRT) technology and deliver high-precision positioning and adaptive proton therapy in a simple workflow. Clinicians will be able to track anatomical changes throughout the course of treatment and adapt the treatment plan as needed to ensure accurate proton dose delivery.
ImagingRing will be fully integrated into optimized workflows with the MEVION S250 Series and Verity Patient Positioning System. Together with Mevion’s 6D robotic treatment couch, it enables detailed imaging of the tumor and organs at risk with the patient positioned at the treatment isocenter.
“By working with medPhoton, Mevion delivers a full suite of best-in-class integrated volumetric imaging solutions for IGRT. The stereotactic integration of in-room cone beam CT scanning for high-precision positioning and adaptive proton therapy represents the most advanced cone beam CT based IGRT available in proton therapy,” said Joseph K. Jachinowski, the president and CEO of Mevion Medical Systems. “Combining the rapid scan speed and image quality of the medPhoton CT imaging with the precision of the MEVION S250 Series is yet another example of how Mevion proton therapy delivers high quality proton treatments with successful clinical, operational and business models for cancer centers of all sizes.”
More information about the medPhoton partnership, HYPERSCAN with Adaptive Aperture, and the clinical and operational advantages of the MEVION S250 Series will be available at ESTRO booth #2500 in Vienna, Austria, from May 5 – 9, 2017.
About Mevion Medical Systems®
Mevion Medical Systems, Inc. is a leading provider of compact proton therapy systems for cancer care. Mevion is based in Littleton, Massachusetts, with international offices in the Netherlands, Japan and China. For more information, please visit www.mevion.com.
About the MEVION S250 Series™
The MEVION S250 Series offers the smallest, most advanced proton therapy solution available today. Its unique gantry-mounted proton accelerator provides superior treatment delivery, reduces complexity and cost, and significantly streamlines operations. No other proton therapy system can match the quality, size, cost and efficiency of the MEVION S250 Series.
The MEVION S250 Series includes:
- MEVION S250 Proton Therapy System®, offering highly stable, next-generation volumetric delivery capabilities
- MEVION S250i Proton Therapy System™ with HYPERSCAN™ with Adaptive Aperture™, overcoming pencil beam scanning uncertainties by delivering robust IMPT treatment at hyper-speed
- MEVION S250mx™, making proton therapy fully scalable, with two, three and four room designs that are inherently redundant and support 100% facility uptime
The MEVION S250i Proton Therapy System with HYPERSCAN with Adaptive Aperture is not yet FDA cleared.